Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    CX-01 | "Acute Myeloid Leukemia"

CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02995655
Recruitment Status : Active, not recruiting
First Posted : December 16, 2016
Last Update Posted : December 17, 2018
Sponsor:
Collaborator:
Cantex Pharmaceuticals
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:

The investigators hypothesize that CX-01 will disrupt the bone marrow microenvironment and increase the cytotoxic effects of azacitidine on myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) hematopoietic stem cells by disrupting the High-mobility group box protein 1 (HMGB1) interaction with toll-like receptor 4 (TLR4) and receptors for advanced glycation end products (RAGE), the CXC chemokine CXCL12/chemokine receptor 4 (CXCR4) axis, and by disrupting other leukocyte and vascular adhesion molecules. In addition, CX-01 may also help promote count recovery after treatment given its affinity for platelet factor-4 (PF4).

The selection of CX-01 dose for study in relapsed or refractory MDS and AML has been based upon the dual requirements to have sufficient drug administered to have potential activity but without clinically significant anticoagulation. The study dose chosen (4 mg/kg bolus followed by 0.25 mg/kg/hour) fulfills both of these criteria. In addition, this dose is expected to result in serum levels of CX-01 which are significantly higher than the IC90 identified in preclinical studies for inhibition of HMGB1-RAGE, toll-like receptor 2 (TLR2) and TLR4 interaction. Therefore, the chosen dose represents a rational balance between effective dosing and safety in thrombocytopenic patients with MDS and AML. This dose was previously established to be safe and tolerable when combined with cytarabine and idarubicin in patients with AML.


Condition or disease Intervention/treatment Phase
Myelodysplastic Syndromes Acute Myeloid Leukemia AML MDS Drug: CX-01 Drug: Azacitidine Procedure: Bone marrow biopsy Procedure: Peripheral blood draw Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Actual Study Start Date : April 7, 2017
Actual Primary Completion Date : September 13, 2018
Estimated Study Completion Date : August 30, 2019


Arm Intervention/treatment
Experimental: CX-01 + Azacitidine
  • CX-01 will be administered as a 5-minute bolus infusion at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle. The dose of CX-01 should be calculated based on actual body weight (kg) as measured on Day 1 of each cycle.
  • Azacitidine will be administered as a 15-minute intravenous infusion at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle. Azacitidine dose should be calculated based on actual body weight and height to determine BSA. CX-01 may be administered before or after azacitidine, at the discretion of the treating physician.
  • Up to 6 cycles of treatment allowed
Drug: CX-01
CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
Other Names:
  • 2-O, 3-O desulfated heparin
  • ODSH

Drug: Azacitidine
Azacitidine at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle.
Other Names:
  • Vidaza®
  • Ladakamycin

Procedure: Bone marrow biopsy
-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study

Procedure: Peripheral blood draw
-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study




Primary Outcome Measures :
  1. Overall response rate (partial response or higher) [ Time Frame: 30 days following completion of treatment (estimated to be 28 weeks) ]
    • Overall response rate = the percentage of patients obtaining partial response or higher
    • Patients will be assessed for response according to modified International Working Group (IWG) criteria


Secondary Outcome Measures :
  1. Progression-free survival (PFS) [ Time Frame: Up to 5 years ]
    • The interval from the date of first dose of study drug to disease progression or death.
    • Described by median time-to-event and a 95% confidence interval, if estimable, using Kaplan-Meier models

  2. Disease-free survival (DFS) [ Time Frame: Up to 5 years ]
    • The interval from the date of first documentation of a CR to date of recurrence or death. This is determined only for patients achieving a CR
    • Described by median time-to-event and a 95% confidence interval, if estimable, using Kaplan-Meier models

  3. Overall survival (OS) [ Time Frame: Up to 5 years ]
    • The date of first dose of study drug to the date of death from any cause.
    • Described by median time-to-event and a 95% confidence interval, if estimable, using Kaplan-Meier models

  4. Safety and tolerability of regimen as measured by adverse events tabulated by patient [ Time Frame: 30 days following completion of therapy (estimated to be 28 weeks) ]
    -The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 will be utilized for all toxicity reporting.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • One of the following diagnoses:

    • MDS with International Prostate Symptom Score (IPSS) score of INT-1 or higher and one of the following:

      • Symptomatic anemia with either hemoglobin < 10.0 g/dL or requiring red blood cell (RBC) transfusion
      • Thrombocytopenia with a history of two or more platelet counts < 50,000/µL or a significant hemorrhage requiring platelet transfusions
      • Neutropenia with two or more absolute neutrophil count (ANC) < 1,000/µL
    • Non-M3 AML
  • Prior treatment with ≥ 4 cycles of a hypomethylating agent (decitabine or azacitidine) without response OR documented disease progression on or after hypomethylating agent therapy
  • Age ≥ 18 years old
  • Adequate renal and hepatic function defined as all of the following:

    • total bilirubin ≤ 1.5 x upper limit of normal (ULN), except in cases of Gilbert's disease
    • aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
    • serum creatinine < 2.0 x ULN
  • Peripheral blood blast count < 10,000/ µL.
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Females must be surgically or biologically sterile or postmenopausal or, if of childbearing potential, must agree to use an adequate method of contraception during the study until 30 days after the last treatment. Males must be surgically or biologically sterile or agree to use an adequate method of contraception during the study until 30 days after the last treatment.
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).

Exclusion Criteria:

  • Prior allogeneic stem cell transplant
  • Central nervous system (CNS) leukemia
  • Diagnosed with AML and eligible for standard induction chemotherapy or stem cell transplantation.
  • At an increased risk of hemorrhage.
  • Known allergies, hypersensitivity, or intolerance to any form of heparin or azacitidine
  • Presence of significant active bleeding or condition requiring maintenance of a platelet count > 50,000/µL
  • Presence of any condition requiring any form of anticoagulant therapy (heparin flushes for IV catheter are permitted)
  • Receiving concomitant chemotherapy, radiation therapy, or immunotherapy during the duration of treatment on protocol, or within 21 days prior to enrollment
  • Known seropositivity for or active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV). Patients who are seropositive because of hepatitis B virus vaccine are eligible.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative pregnancy test within 28 days of study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02995655


Locations
Layout table for location information
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
Sponsors and Collaborators
Washington University School of Medicine
Cantex Pharmaceuticals
Investigators
Layout table for investigator information
Principal Investigator: Peter Westervelt, M.D., Ph.D. Washington University School of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT02995655     History of Changes
Other Study ID Numbers: 201608032
CNTX-CX-01-2016-MDS-1 ( Other Identifier: Cantex Pharmaceuticals )
First Posted: December 16, 2016    Key Record Dates
Last Update Posted: December 17, 2018
Last Verified: December 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Syndrome
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Preleukemia
Disease
Pathologic Processes
Neoplasms by Histologic Type
Neoplasms
Bone Marrow Diseases
Hematologic Diseases
Precancerous Conditions
Azacitidine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors